EXTON, Pa.--(BUSINESS WIRE)--Morphotek, Inc., a subsidiary of Eisai Co., Ltd. announced today that the company has received $2.3M funding approval from the U.S. Department of Defense to support the development of biologic-based monoclonal antibody (mAb) therapies against biowarfare agents.
